Overview

Veltassa is a medicine used for treating adults and adolescents aged 12 years and above with high levels of potassium in the blood (hyperkalaemia). Hyperkalaemia can cause serious heart problems and muscle weakness.

Veltassa contains the active substance patiromer.

Veltassa is available as sachets containing a powder for mixing with water, liquid or soft food and is to be taken by mouth once daily. The recommended starting dose depends on the patient’s age; the dose is adjusted based on the patient’s blood levels of potassium.

The medicine can only be obtained with a prescription. For more information about using Veltassa, see the package leaflet or contact your doctor or pharmacist.

When Veltassa is taken by mouth, the active substance, patiromer, remains in the gut where it attaches tightly to potassium to form a compound that is then passed out in the stool. In this way, patiromer draws potassium from the body into the gut and so reduces the amount of potassium in the blood.

One main study involving adults with chronic kidney disease who had hyperkalaemia found that Veltassa is effective in reducing potassium levels in the blood.

In the first part of the study, 243 patients with hyperkalaemia (with an average potassium level of 5.6 mmol/litre) were treated with Veltassa. After 4 weeks of treatment, their potassium level fell on average by 1.0 mmol/litre.

The second part of the study compared Veltassa with placebo (a dummy treatment) in 107 patients whose potassium level had fallen with Veltassa during the first part of the study. After 4 weeks, the average potassium level did not change in patients who received Veltassa but it went back up by an average of 0.7 mmol/litre in patients who received placebo.

Another study involved 14 adolescents aged 12 years and above with hyperkalaemia (with an average potassium level of 5.5 mmol/litre). After 14 days of treatment with Veltassa, their potassium levels fell on average by 0.5 mmol/litre. This effect persisted, leading to an average reduction by 1.1 mmol/litre after 26 weeks of treatment.

For the full list of side effects and restrictions with Veltassa, see the package leaflet. The most common side effects with Veltassa (which may affect up to 1 in 10 people) include constipation, diarrhoea, abdominal (belly) pain, wind and low levels of magnesium in the blood.

The European Medicines Agency decided that Veltassa’s benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that there is a need for effective treatment of hyperkalaemia and Veltassa achieves a meaningful lowering of potassium levels. The side effects are relatively moderate but the doctor should take them into account when considering treatment with Veltassa.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veltassa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Veltassa are continuously monitored. Suspected side effects reported with Veltassa are carefully evaluated and any necessary action taken to protect patients.

Veltassa received a marketing authorisation valid throughout the EU on 19 July 2017.

Veltassa : EPAR - Medicine overview

български (BG) (138.42 KB - PDF)
español (ES) (116.26 KB - PDF)
čeština (CS) (136.75 KB - PDF)
dansk (DA) (115.5 KB - PDF)
Deutsch (DE) (118.63 KB - PDF)
eesti keel (ET) (115.61 KB - PDF)
ελληνικά (EL) (136.66 KB - PDF)
français (FR) (117.27 KB - PDF)
hrvatski (HR) (136.66 KB - PDF)
italiano (IT) (115.43 KB - PDF)
latviešu valoda (LV) (143.56 KB - PDF)
lietuvių kalba (LT) (137.32 KB - PDF)
magyar (HU) (136.54 KB - PDF)
Malti (MT) (140.57 KB - PDF)
Nederlands (NL) (116.33 KB - PDF)
polski (PL) (138.35 KB - PDF)
português (PT) (117.63 KB - PDF)
română (RO) (135.16 KB - PDF)
slovenčina (SK) (137.59 KB - PDF)
slovenščina (SL) (135.14 KB - PDF)
Suomi (FI) (113.82 KB - PDF)
svenska (SV) (114.86 KB - PDF)

Veltassa : EPAR - Risk management plan

Product information

Veltassa : EPAR - Product Information

български (BG) (434.75 KB - PDF)
español (ES) (301.65 KB - PDF)
čeština (CS) (461.95 KB - PDF)
dansk (DA) (321.05 KB - PDF)
Deutsch (DE) (489.25 KB - PDF)
eesti keel (ET) (445.57 KB - PDF)
ελληνικά (EL) (436.04 KB - PDF)
français (FR) (322.66 KB - PDF)
hrvatski (HR) (462.34 KB - PDF)
íslenska (IS) (302.7 KB - PDF)
italiano (IT) (434.73 KB - PDF)
latviešu valoda (LV) (468.39 KB - PDF)
lietuvių kalba (LT) (463.37 KB - PDF)
magyar (HU) (399.22 KB - PDF)
Malti (MT) (485.78 KB - PDF)
Nederlands (NL) (432.5 KB - PDF)
norsk (NO) (438.32 KB - PDF)
polski (PL) (427.42 KB - PDF)
português (PT) (311.32 KB - PDF)
română (RO) (393.97 KB - PDF)
slovenčina (SK) (587.71 KB - PDF)
slovenščina (SL) (567.24 KB - PDF)
Suomi (FI) (428.31 KB - PDF)
svenska (SV) (344.63 KB - PDF)

Latest procedure affecting product information: X/0031/G

05/01/2024

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Veltassa: EPAR – All authorised presentations

български (BG) (45.13 KB - PDF)
español (ES) (49.87 KB - PDF)
čeština (CS) (40.03 KB - PDF)
dansk (DA) (23.45 KB - PDF)
Deutsch (DE) (27.46 KB - PDF)
eesti keel (ET) (19.69 KB - PDF)
ελληνικά (EL) (43.94 KB - PDF)
français (FR) (23.62 KB - PDF)
hrvatski (HR) (37.27 KB - PDF)
íslenska (IS) (23.39 KB - PDF)
italiano (IT) (19.33 KB - PDF)
latviešu valoda (LV) (45.64 KB - PDF)
lietuvių kalba (LT) (41.55 KB - PDF)
magyar (HU) (46.92 KB - PDF)
Malti (MT) (44.26 KB - PDF)
Nederlands (NL) (44.17 KB - PDF)
norsk (NO) (23.55 KB - PDF)
polski (PL) (49.24 KB - PDF)
português (PT) (43.42 KB - PDF)
română (RO) (70.5 KB - PDF)
slovenčina (SK) (44.58 KB - PDF)
slovenščina (SL) (42.74 KB - PDF)
Suomi (FI) (23.75 KB - PDF)
svenska (SV) (23.74 KB - PDF)

Product details

Name of medicine
Veltassa
Active substance
patiromer sorbitex calcium
International non-proprietary name (INN) or common name
patiromer
Therapeutic area (MeSH)
Hyperkalemia
Anatomical therapeutic chemical (ATC) code
V03AE09

Pharmacotherapeutic group

Drugs for treatment of hyperkalemia and hyperphosphatemia

Therapeutic indication

Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.

Authorisation details

EMA product number
EMEA/H/C/004180
Marketing authorisation holder
Vifor Fresenius Medical Care Renal Pharma France

100-101 Terrasse Boieldieu
Tour Franklin La Defense 8
Paris La Defense
Cedex 92042
Paris
France

Opinion adopted
18/05/2017
Marketing authorisation issued
19/07/2017
Revision
8

Assessment history

Veltassa : EPAR - Procedural steps taken and scientific information after the authorisation

Veltassa-H-C-004180-X-0031-G : EPAR - Assessment report - Variation

CHMP post-authorisation summary of positive opinion for Veltassa (X-31-G)

Veltassa : EPAR - Public assessment report

CHMP summary of positive opinion for Veltassa

Topics

This page was last updated on

How useful do you find this page?